KRYS
$251.68-6.32 (-2.45%)
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremag...
Recent News
Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data
Ocugen faces rising cash burn and dilution risk as it advances late-stage gene therapy programs, with 2026-2027 data and filings set to drive volatility.
OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch
Ocugen lines up key gene therapy catalysts through 2027, with pivotal data, filings, and milestones across three eye programs set to drive stock volatility.
Why Is Krystal Biotech (KRYS) Down 11.5% Since Last Earnings Report?
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is It Too Late To Consider Krystal Biotech (KRYS) After Strong Multi‑Year Share Gains?
Wondering whether Krystal Biotech at around US$256 per share still offers value, or if most of the upside has already played out? This article breaks down what the current price might be implying. The stock has had a mixed run, with a 1.8% decline over the last week and a 7.3% decline over the last month, but it is still up 3.8% year to date and 36.0% over the last year, with a very large return over the last 3 years and a 251.9% gain over 5 years. Recent attention on Krystal Biotech has...
Updated YJUVEK Label and KB803 Progress Could Be A Game Changer For Krystal Biotech (KRYS)
In September 2025, the FDA approved an updated label for Krystal Biotech’s beremagene geperpavec-svdt (B-VEC/YJUVEK), reflecting evolving treatment guidance for epidermolysis bullosa and reinforcing its role in this rare disease space. This label update, alongside progress on Krystal’s pipeline candidate KB803, underscores how regulatory evolution and innovation may reshape the epidermolysis bullosa treatment landscape. We’ll now examine how the updated FDA label for B-VEC/YJUVEK may...